Outcomes after biochemical or clinical progression in patients with multiple myeloma

Almost all patients with multiple myeloma (MM) eventually relapse, either asymptomatically or with end-organ damage. However, it remains unclear whether initiating therapy at the time of biochemical progression (BP) improves the outcomes compared with initiating therapy at the clinical progression (...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman-Mazur, Sarah, Visram, Alissa, Kapoor, Prashant, Dispenzieri, Angela, Lacy, Martha Q., Gertz, Morie A., Buadi, Francis K., Hayman, Suzanne R., Dingli, David, Kourelis, Taxiarchis, Gonsalves, Wilson, Warsame, Rahma, Muchtar, Eli, Leung, Nelson, Binder, Moritz, Fonder, Amie, Hobbs, Miriam, Hwa, Yi Lisa, Kyle, Robert A., Rajkumar, S. Vincent, Kumar, Shaji K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025108/
https://www.ncbi.nlm.nih.gov/pubmed/35413102
http://dx.doi.org/10.1182/bloodadvances.2022007082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025108/
https://www.ncbi.nlm.nih.gov/pubmed/35413102
http://dx.doi.org/10.1182/bloodadvances.2022007082

Ejemplares similares